Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ataluren in nonsense mutation dystrophinopathy
NCT01826487Phase 3Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Mar 2013
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of ataluren in Duchenne muscular dystrophy (DMD), sponsored by PTC Therapeutics, Inc.. Started Mar 2013; status: completed.
02
Drugs
ataluren
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT01826487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01826487.